COVID-19 | Discover the latest peer-reviewed research articles from the Eastern Mediterranean Region
COVID-19 | Discover the latest peer-reviewed research articles from the Eastern Mediterranean Region
COVID-19 | Discover the latest publications published by WHO Regional Office for the Eastern Mediterranean
COVID-19 | Discover the latest publications published by WHO Regional Office for the Eastern Mediterranean

Virtual Health Sciences Library

  • Home
  • Search
  • Knowledge Base
  • Get a journal indexed in the Index Medicus
  • MyVHSL
  1. Home
  2. IMEMR
  3. Search Result
  4. Serum reverse triiodothyronine in nephrotic patients

Serum reverse triiodothyronine in nephrotic patients

Authors

Abou Zeid, Mohamed H.
Med. J. Cairo Univ. 1987; 55 (3): 525-40
Medical Journal of Cairo University [The]
Journal Country: Egypt
P-ISSN: 0045-3803
MeSH Terms: Nephrotic Syndrome
Broad Subjects: ,Thyroid Function Tests ,Triiodothyronine, Reverse
Citation: Mohamed H. Abou Zeid, Serum reverse triiodothyronine in nephrotic patients. Med. J. Cairo Univ. 1987; 55 (3): 525-40

Abstract English

This work included fifteen nephrotic patients [eight females and seven males] in addition to ten healthy control subjects [six females and four males]. Patients and controls were subjected to the following investigations; serum thyroxine, triiodothyronine, thyroxine binding globulin, thyroid stimulating hormone and reverse triiodothyronine. The results showed that patients with nephrotic syndrome had low mean total serum thyroxine T4 [5. 99 +/- 0. 41 Ugm/dl] and thyroxine binding globulin TBC levels [23. 1 +/- 0. 38 Ugm/dl]. The mean serum reverse triiodothyronine levels were within normal, while T3/T4 ratio was higher in nephrotic patients than the control subjects. Patients with nephrotic syndrome and ascites had a lower TBG than nephrotic patients with no ascites. Patients with nephrotic syndrome with serum creatinine levels more than 2 mg/dl had a significantly higher rT3 than nephrotic patients with normal kidney functions

Request full text

Subscribe to VHSL Newsletters

© 2023 WHO – EMRO